{
    "filename": "0001193125-25-220480_primary_doc.xml",
    "path": "d:\\Files\\Code\\Funkles-SEC\\FunklesScraper\\..\\filings_cache\\0001193125-25-220480_primary_doc.xml",
    "date": "2025-09-26",
    "form": "SCHEDULE 13D",
    "file_type": "SCHEDULE 13D",
    "original_filename": "primary_doc.xml",
    "issuer": "Semnur Pharmaceuticals, Inc.",
    "reporting_persons": [
        "Scilex Holding Company",
        "Scilex, Inc."
    ],
    "cik": "0001584541",
    "label": "Plans to influence or control the company",
    "summary": "Scilex Holding Company (SHC) and its subsidiary, Scilex, Inc., report beneficial ownership in Semnur Pharmaceuticals, Inc. (formerly Denali Capital Acquisition Corp.) following a business combination completed on September 22, 2025. SHC now beneficially owns 188,554,849 shares of Common Stock, representing 79.89% of the class, plus 5,423,606 shares of Series A Preferred Stock, totaling 80.34% of the issuer's voting power. Subsequent to the combination, the Reporting Persons sold 12,500,000 shares of Common Stock to Biconomy PTE.LTD for $16.00 per share, payable in Bitcoin, and SHC also maintains significant governance rights via a Stockholder Agreement.",
    "share %": null
}